Credit Suisse’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Credit Suisse’s Portfolio EFTRW Stock Details EFTRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-47,299	Closed	-$42K	–	4456
2021 Q4	$42K	Sell	47,299 -102,701	-68%	-$129K	﹤0.01%	4428
2021 Q3	$245K	Buy	+150,000	New	+$182K	﹤0.01%	4161

Other funds holding EFTRW

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

III Capital Management Boca Raton, Florida $344M AUM 11.22% 1-Year Est. Return

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Credit Suisse's EFTRW Position: Q1 2022 in Review

Credit Suisse sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q1 2022, closing a stake of 47,299 shares — an estimated $42K sold.

Credit Suisse first reported a position in EFTRW in Q3 2021 and held it in 2 quarters. The position peaked at $245K in Q3 2021. 17 funds tracked by Wall St. Rank hold EFTRW as of Q1 2022.

Credit Suisse reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q1 2022 after selling out during the quarter.
Credit Suisse sold 47,299 eFFECTOR Therapeutics, Inc. Warrant shares in Q1 2022, an estimated $42K.
Credit Suisse first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q3 2021 and held it in 2 quarters.
Credit Suisse's eFFECTOR Therapeutics, Inc. Warrant position peaked at $245K in Q3 2021.
17 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q1 2022.

Based on Credit Suisse's 13F filing for Q1 2022, filed 16 May 2022.